Table 1.
Clinical characteristics and medications of the study population.
| Characteristics | Statin (n = 26) | No statin (n = 12) | P value |
|---|---|---|---|
| Age, yr (IQR) | 72.0 (66.0–77.3) | 71.5 (67.3–76.7) | 0.9249 |
| Males, n (%) | 14 (53.8) | 7 (58.3) | 1.0000 |
| CV risk factors | |||
| Blood pressure, mmHg | |||
| Systolic (IQR) | 130.0 (125.0–141.3) | 130.0 (125.0–140.0) | 0.6826 |
| Diastolic (IQR) | 85.0 (80.0–90.0) | 80.5 (80.0–84.5) | 0.4686 |
| Waist Circumference, cm (IQR) | 91.0 (88.0–98.0) | 91.5 (90.0–95.0) | 0.7414 |
| Current smoking, n (%) | 7 (26.9) | 3 (25.0) | 1.0000 |
| Type 2 diabetes, n (%) | 11 (42.3) | 3 (25.0) | 0.4722 |
| Dislipidemia, n (%) | 16 (61.5) | 4 (33.3) | 0.1643 |
| Hypertension, n (%) | 21 (80.8) | 10 (83.3) | 1.0000 |
| Chronic CAD*, n (%) | 7 (26.9) | 3 (25) | 1.0000 |
| Carotid stenosis % lumen (IQR) | 75 (70–80) | 80 (70–85) | 0.2349 |
| Biological parameters | |||
| Total WBC†, number ×109/L (IQR) | 6.35 (5.53–7.43) | 6.56 (5.60–8.98) | 0.4053 |
| Neutrophils, number ×109/L (IQR) | 3.90 (3.38–5.05) | 4.36 (3.57–6.14) | 0.4996 |
| Lymphocytes, number ×109/L (IQR) | 1.58 (1.24–1.96) | 1.56 (1.12–1.84) | 0.6716 |
| Monocytes, number ×109/L (IQR) | 0.37 (0.30–0.49) | 0.44 (0.38–0.53) | 0.0429 |
| Red blood cells, number ×1012/L (IQR) | 4.60 (4.10–4.85) | 4.65 (4.53–5.00) | 0.2513 |
| Platelet, number ×109/L (IQR) | 207.5 (178.8–238.8) | 188.5 (175.5–219.8) | 0.5096 |
| Plasma fibrinogen, g/L (IQR) | 3.65 (3.25–4.79) | 4.09 (3.69–5.11) | 0.3146 |
| Serum total-c‡, mg/dl (IQR) | 189.0 (164.0–215.0) | 202.0 (159.3–209.3) | 0.6150 |
| Serum LDL-c§, mg/dl (IQR) | 104.0 (81.2–130.0) | 118.8 (77.0–132.2) | 0.6380 |
| Serum HDL-c||, mg/dl (IQR) | 60.0 (41.5–69.0) | 49.5 (41.5–64.0) | 0.4754 |
| Serum triglycerides, mg/dl (IQR) | 124.0 (83.5–160.0) | 85.0 (68.0–118.8) | 0.2237 |
| Serum glycaemia, mg/dl (IQR) | 101.0 (96.5–153.0) | 111.0 (95.8–124.0) | 0.6497 |
| Serum insulinemia, mU/L (IQR) | 7.5 (5.8–16.3) | 5.6 (3.7–12.2) | 0.0747 |
| Serum C-peptidemia, μg/L (IQR) | 2.35 (1.92–3.97) | 2.06 (1.60–2.61) | 0.1894 |
| Antiplatelets, n (%) | 23 (88.5) | 10 (83.3) | 0.6426 |
| Diuretics, n (%) | 2 (7.7) | 4 (33.3) | 0.0661 |
| ACE# inhibitors, n (%) | 2 (7.7) | 1 (8.3) | 0.2295 |
| ARBs**, n (%) | 11 (42.3) | 6 (50.0) | 0.7342 |
| Beta-blockers, n (%) | 10 (38.5) | 3 (25.0) | 0.4859 |
| Calcium channel blockers, n (%) | 9 (34.6) | 4 (33.3) | 1.0000 |
| Oral antidiabetics, n (%) | 7 (26.9) | 3 (25.0) | 1.0000 |
Continuous variables are expressed as median (interquartile range (IQR)).
*CAD: coronary artery disease.
†WBC: white blood cells.
‡total-c: total cholesterol.
§LDL-c: low-density lipoprotein cholesterol.
||HDL-c: high-density lipoprotein cholesterol.
#ACE: angiotensin converting enzyme.
**ARBs: angiotensin receptor blockers.